Vera MC, Pisani GB, Biancardi ME, Bottai H, de Luján AM, Quintana AB

Language: English
References: 18
Page: 259-266
PDF size: 220.49 Kb.

ABSTRACT

Background. One established model to induce hepatic preneoplasia (HP) (DEN 150) uses diethylnitrosamine (DEN) as initiator agent and 2-acetylaminofluorene (2-AAF) as a promoter drug. In addition, both chemicals cause liver cholestasis and fibrosis. Aim. We compared DEN 150 model with another adapted by us, DEN 200 to simplify the first one and to evaluate the effectiveness of both treatments to induce HP in rats. Material and methods. Male Wistar rats were divided in 3 groups: controls; DEN 150 (rats received 2 doses of DEN, 150 mg/kg body weight, 2 weeks apart, and then 2-AAF, 20 mg/kg body weight, 4 doses per week during 3 weeks); and DEN 200 (rats received a single dose of DEN 200 mg/kg body weight, and 2 weeks apart 2-AAF, 20 mg/kg body weight, 2 doses per week during 3 weeks). Four hepatic enzymes, prothrombin time percentage, the number of bile ductules, total collagen amount, the number of altered hepatic foci (AHF) per liver and the percentage of liver occupied by foci were analyzed. Results. There were no differences in the number of AHF per liver between treated groups. Rats from DEN 200 group showed a significant diminution in the volume of liver occupied by foci. DEN 200 group had no fibrosis and better hemostatic conditions than DEN 150 group. Both groups developed cholestasis. Conclusion. In conclusion, both protocols are good alternatives to induce HP in rats and the new protocol proposed is an effective and a simple methodology to provide subclinic states of liver cancer.

REFERENCES

1. Solt DB, Farber E. Rapid Emergence of Carcinogen-Induced Hyperplastic Lesions in a New Model for the Sequential Analysis of Liver Carcinogenesis. Am J Pathol 1977; 88: 595-618.

2. Chakraborty T, Pandey N, Chatterjee A, Ghosh B, Rana B, Chatterjee M. Molecular basis of anticlastogenic potential of vanadium in vivo during the early stages of diethylnitrosamine- induced hepatocarcinogenesis in rats. Mutat Res 2006; 609: 117-28.

3. Mills J, Jirtle R, Boyer I. Mechanisms of liver tumor promotion. In: Jirtle RL (ed.). Liver regenetation and carcinogenesis. San Diego: Academic Press; 1995, p. 199-226.

4. de Lujan Alvarez M, Cerliani JP, Monti J, Carnovale C, Ronco MT, Pisani G, Lugano MC, et al. The in vivo apoptotic effect of interferon alfa-2b on rat preneoplasia liver involves bax protein. Hepatology 2002; 35: 824-33.

5. Institute for Laboratory Animal Research. Guide for the Care and Use of Laboratory Animals. Washington DC: National Academies Press; 2010.

6. Greer JP, Foerster J, Rodger GM, Paraskevas F, Glader B, Arber DA, Means RT, Jr. Hemostasis. In: Greer JP (ed.). Wintrobe’s Clinical Hematology. Vol. 1. 12th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2009, p. 468-630.

7. Imai T, Masui T, Ichinose M, Nakanishi H, Yanai T, Masegi T, Muramatsu M, et al. Reduction of glutathione S-transferase P-form mRNA expression in remodeling nodules in rat liver revealed by in situ hybridization. Carcinogenesis 1997; 18: 545-51.

8. Saltykov SA. The determination of the size distribution of particles in an opaque material for measurement of the size distribution of their sections. In: Elias H (ed.). Proceedings of the Second International Congress for Stereology. Chicago: Springer-Verlag; 1967, p. 163-73.

9. Bessone V, Pizarro MD, Izaguirre MF, Furno G, Biancardi ME, Baumgartner N, Rodriguez J, et al. Structural, ultrastructural and functional studies of human cardiac valve allografts that suffered an increment of the cryostorage temperature. CryoLetters 2011; 32: 69-80.

10. Rodriguez-Garay EA, Rodriguez GP, Pisani GB, Taborda M, Viglianco RA. Reversible cholestasis induced by experimental partial obstruction of the bile duct; Biochemical, morphometric and hepatic transport kinetic studies. Pathophysiology 2004; 11: 7-15.

11. Johnston D. Special considerations in interpreting liver function tests. Am Fam Physician 1999; 59: 2223-30.

12. Brown SS, Kalow W, Pilz W, Whittaker M, Woronick CL. The plasma cholinesterases: A new perspective. In: Albert L. Latner AL, Schwartz MK (eds.). Advances in Clinical Chemistry. Vol. 22. New York: Academic Press Inc; 1981, p. 2-125.

13. Pitot H. Altered hepatic foci: their role in murine hepatocarcinogenesis. Annu Rev Pharmacol Toxicol 1990; 30: 465-500.

14. Dragan YP, Hully JR, Nakamura J, Mass MJ, Swenberg JA, Pitot HC. Biochemical events during initiation of rat hepatocarcinogenesis. Carcinogenesis 1994; 15: 1451-8.

15. Espandiari P, Robertson LW, Srinivasan C, Glauert HP. Comparison of different initiations protocols in the resistant hepatocyte model. Toxicology 2005; 206: 373-81.

16. Batta A. Comparative study of serum 5’ nucleotidase, alkaline phosphatase, aminotransferases and bilirubin in hepatobiliary diseases. Int J Cur Biomed Phar Res 2011; 1: 93-7.

17. Yang F, Gaudio E, Onori P, Wise C, Alpini G, Glaser S. Mechanisms of Biliary Damage. J Cell Death 2010; 3: 13-21.

18. Sirica AE, Elmore LW, Williams TW, Cole SL. Differentiation potential of hyperplastic bile ductular epithelial cells in rat models of hepatic injury and cholangiocarcinogenesis. In: Sirica AE (ed.). The role of cell types in hepatocarcinogenesis. USA: CRC Press Inc.; 1992, p. 190.